Breast Cancer Research and Treatment

, Volume 92, Issue 2, pp 151–156

Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy

  • Arti Hurria
  • Kelly Brogan
  • Katherine S. Panageas
  • Carol Pearce
  • Larry Norton
  • Ann Jakubowski
  • Marjorie Zauderer
  • Jane Howard
  • Clifford Hudis
Report

Summary

Objective. To retrospectively determine the relationship of age to toxicity from adjuvant chemotherapy for breast cancer.

Design and Methods We identified 1405 consecutive patients age 65 or older with primary invasive breast cancer who were seen at Memorial Sloan-Kettering Cancer Center from January 1998 to December 2000. Patients selected from this cohort for analysis were aged 65 or older at diagnosis; received their follow-up care at Memorial Sloan-Kettering Cancer Center; had stage I, II, or III breast cancer; and received adjuvant chemotherapy consisting of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil), an anthracycline-based regimen (AC [doxorubicin and cyclophosphamide], or AC-T [AC and paclitaxel or docetaxel]). Exclusion criteria included prior chemotherapy or previous breast cancer.

Results. One hundred thirty-two patients were included in this study, with a mean age of 70 (range 65–79). Comorbidity measured by the Charlson comorbidity index was low: score 0 (83%), 1 (12%), 2 (5%); with stages: I(18%), IIA (41%), IIB (27%), IIIA (8%), IIIB (6%), T1Nx (1%). Patients receiving an anthracycline-based regimen were more likely to experience grade 3 or 4 toxicity (p=0. 01), require hospitalization (p<0.001), and/or develop febrile neutropenia (p<0.001). Treatment delays due to myelosuppression occurred more frequently in patients receiving CMF (p<0.001). The type of chemotherapy regimen (anthracycline compared to CMF) was a better predictor for toxicity than increased age or comorbidity score.

Conclusions. In this cohort of older patients with breast cancer, the risk for toxicity from adjuvant chemotherapy depended more on the type of regimen (anthracycline vs. CMF) than the patient’s chronological age.

Keywords

breast cancer chemotherapy older patient 

Abbreviations

AC

(doxorubicin and cyclophosphamide)

AC-T

(AC and paclitaxel or docetaxel)

CALGB

Cancer and Leukemia Group B

CMF

(cyclophosphamide, methotrexate, and 5-fluorouracil)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal, A, Tiwari, RC, Murray, T, Ghafoor, A, Samuels, A, Ward, E, Feuer, EJ, Thun, MJ 2004Cancer Statistics, 2004CA Cancer J Clin54829Google Scholar
  2. 2.
    Armstrong, K, Eisen, A, Weber, B 2000Assessing the risk of breast cancerN Engl J Med342564571Google Scholar
  3. 3.
    Yancik, R 1997Cancer burden in the aged: an epidemiologic and demographic overviewCancer8012731283Google Scholar
  4. 4.
    Newcomb, PA, Carbone, PP 1993Cancer treatment and age: patient perspectivesJ Natl Cancer Inst8515801584Google Scholar
  5. 5.
    Busch, E, Kemeny, M, Fremgen, A, Osteen, RT, Winchester, DP, Clive, RE 1996Patterns of breast cancer care in the elderlyCancer78101111Google Scholar
  6. 6.
    Newschaffer, CJ, Penberthy, L, Desch, CE, Retchin, SM, Whittemore, M 1996The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancerArch Intern Med1568590Google Scholar
  7. 7.
    Bergman, L, Dekker, G, Leeuwen, FE , Huisman, SJ, Dam, FS, Dongen, JA 1991The effect of age on treatment choice and survival in elderly breast cancer patientsCancer6722272234Google Scholar
  8. 8.
    Yancik, R, Ries, LG, Yates, JW 1989Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survivalCancer63976981Google Scholar
  9. 9.
    Hillner, BE, Penberthy, L, Desch, CE, McDonald, MK, Smith, TJ, Retchin, SM 1996Variation in staging and treatment of local and regional breast cancer in the elderlyBreast Cancer Res Treat407586Google Scholar
  10. 10.
    Ballard-Barbash, R, Potosky, AL, Harlan, LC, Nayfield, SG, Kessler, LG 1996Factors associated with surgical and radiation therapy for early stage breast cancer in older womenJ Natl Cancer Inst88716726Google Scholar
  11. 11.
    Hurria, A, Leung, D, Trainor, K, Borgen, P, Norton, L, Hudis, C 2003Factors influencing treatment patterns of breast cancer patients age 75 and olderCrit Rev Oncol Hematol46121126Google Scholar
  12. 12.
    Du, XL, Osborne, C, Goodwin, JS 2002Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancerJ Clin Oncol2046364642Google Scholar
  13. 13.
    Balducci, L, Extermann, M 2000Management of cancer in the older person: a practical approachOncologist5224237Google Scholar
  14. 14.
    Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352(9132): 930–942, 1998Google Scholar
  15. 15.
    Herbsman, H, Feldman, J, Seldera, J, Gardner, B, Alfonso, AE 1981Survival following breast cancer surgery in the elderlyCancer4723582363Google Scholar
  16. 16.
    Muss HB, Berry DA, Weiss RB, Budman DR, Wood WC, Henderson CI, Hudis C, Winer EP, Norton L: Older women with node positive (N+) breast cancer (BC) get similar benefits from adjuvant chemotherapy (Adj) as younger patients (pts): The Cancer and Leukemia Group B (CALGB) experience [abstract]. Am Soc Clin Oncol 2003. Abstract 11Google Scholar
  17. 17.
    Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR 1987A new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis40373383Google Scholar
  18. 18.
    Extermann, M, Balducci, L, Lyman, GH 2000What threshold for adjuvant therapy in older breast cancer patients?J Clin Oncol1817091717Google Scholar
  19. 19.
    Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114): 1451–1467, 1998Google Scholar
  20. 20.
    Balducci, L, Yates, J 2000General guidelines for the management of older patients with cancerOncology (Huntingt)14221227Google Scholar
  21. 21.
    Dees, EC, O’Reilly, S, Goodman, SN, Sartorius, S, Levine, MA, Jones, RJ, Grochow, LB, Donehower, RC, Fetting, JH 2000A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancerCancer Invest18521529Google Scholar
  22. 22.
    Hurria, A, Muss, HB, Cohen, HJ 2003

    Cancer and Aging

    Kufe, D eds. Holland-Frei Cancer MedicineBC DeckerHamilton10931099
    Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Arti Hurria
    • 1
  • Kelly Brogan
    • 1
  • Katherine S. Panageas
    • 1
  • Carol Pearce
    • 1
  • Larry Norton
    • 1
  • Ann Jakubowski
    • 1
  • Marjorie Zauderer
    • 1
  • Jane Howard
    • 1
  • Clifford Hudis
    • 1
  1. 1.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations